Daily Deal Round Up: September 7, 2022 -

SoftBank, Bristol Myers Squibb and Hitachi were among Arsenal Biosciences’ $220m round while MegaChips led a $140m round for Morse Micro.

M&A

Pharmaceutical firm Roche has agreed to acquire a portfolio company, Good Therapeutics, which is a US-based self-regulating therapy developer, for $250m in cash and additional earnouts. The company had secured more than $30m in funding from the corporate’s Roche Venture Fund as well as RiverVest Venture Partners, 3×5 Partners, Digitalis Ventures and Codon Capital.

Funding

Company	Company description	Sector	Country	Round	Round size($m)	Deal date	Investors
Arsenal Biosciences	Programmable cell therapy developer	Healthcare	US	B	220	06/09/2022	SoftBank (SoftBank Vision Fund 2), Bristol Myers Squibb, Hitachi (Hitachi Ventures); Byers Capital,… Subscribe to go deeper GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors. Not sure if you have a subscription? Edison Fu Edison Fu is a reporter and Asia liaison at Global Corporate Venturing. email Linked in LEADERSHIP SOCIETY Informing, connecting, and transforming the global corporate venture capital ecosystem. The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns. Find out more Featured Content FUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database. FUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database. POWERLIST Introducing the GCV Powerlist 2024 POWERLIST Introducing the GCV Powerlist 2024 CVC DIRECTORY Which corporates have venture capital units and what do they focus on? CVC DIRECTORY Which corporates have venture capital units and what do they focus on? Events Webinar: Collaborating with startups - CVC 'platforms' or 'venture client' programs? Aug 14, 2024 Online Find out more All events Events GCV Connect: New Nordics 2024 Sep 16 - Sep 17, 2024 Helsinki (Finland) & Tallinn (Estonia) Find out more All events Events GCV Institute: CVC Investment Programs Sep 24 - Sep 25, 2024 Online Find out more All events Events GCV Institute: Landing the Value of Corporate Venturing Oct 18 - Oct 21, 2024 Online Find out more All events Events GCV Executive Leadership Forum 2024 Oct 24, 2024 Menlo Park, CA (USA) Find out more All events Events Corporate Venture in Brasil 2024 – International Delegation to Brazil Oct 28 - Oct 30, 2024 São Paulo (Brazil) Find out more All events Events GCV Connect: Germany 2024 Oct 29, 2024 Frankfurt (Germany) Find out more All events Events GCV Asia Congress & International Delegation 2024 Nov 11 - Nov 14, 2024 Tokyo (Japan) Find out more All events Events GCVI Summit 2025 Mar 18 - Mar 20, 2025 Monterey, CA (USA) Find out more All events Top News BBC's startup investment arm emerges from stealth mode with metaverse deal Ask the experts — Can we tell the business our portfolio startup will disrupt them? Ex-SoftBank investor Housenbold joins YouTuber MrBeast’s company US healthcare provider Ochsner Health’s CVC launches $10m fund Can Baxus curb luxury drinks fraud by putting bottles on the blockchain? US insurer Liberty Mutual's CVC launches $200m fund About us GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources. Navigation Membership Events Subscribe Newsletters About Us Contact Us © 2024 Mawsonia Ltd. All rights reserved. test reg Login Remember me Forgot password? Not yet subscribed? See your subscription offers here This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More Privacy & Cookies Policy Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. Non-necessary Non-necessary Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. SAVE & ACCEPT

Company

Company description

Sector

Country

Round

Round size($m)

Deal date

Investors

Arsenal Biosciences

Programmable cell therapy developer

Healthcare

220

06/09/2022

SoftBank (SoftBank Vision Fund 2), Bristol Myers Squibb, Hitachi (Hitachi Ventures); Byers Capital,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?

Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.

email Linked in

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

POWERLIST

Introducing the GCV Powerlist 2024

CVC DIRECTORY

Which corporates have venture capital units and what do they focus on?

Events

Webinar: Collaborating with startups - CVC 'platforms' or 'venture client' programs?

Aug 14, 2024
Online

Find out more All events

Events

GCV Connect: New Nordics 2024

Sep 16 -
Sep 17, 2024
Helsinki (Finland) & Tallinn (Estonia)

Find out more All events

Events

GCV Institute: CVC Investment Programs

Sep 24 -
Sep 25, 2024
Online

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

Oct 18 -
Oct 21, 2024
Online

Find out more All events

Events

GCV Executive Leadership Forum 2024

Oct 24, 2024
Menlo Park, CA (USA)

Find out more All events

Events

Corporate Venture in Brasil 2024 – International Delegation to Brazil

Oct 28 -
Oct 30, 2024
São Paulo (Brazil)

Find out more All events

Events

GCV Connect: Germany 2024

Oct 29, 2024
Frankfurt (Germany)

Find out more All events

Events

GCV Asia Congress & International Delegation 2024

Nov 11 -
Nov 14, 2024
Tokyo (Japan)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.